Carregando…
ALMR
Alamar Biosciences, Inc.
NASDAQ· Healthcare· Medical Devices
$30.71-6.94%
Indicadores
- Market cap
- $2.13B
- P/L
- —
- P/L projetado
- —
- P/VP
- 6.8x
- Dividend yield
- —
- EPS
- -$0.72
- ROE
- —
- Margem líquida
- -49.45%
- Crescimento de receita
- +82.10%
- Beta
- —
- Máxima 52 semanas
- $38.54
- Mínima 52 semanas
- $18.85
Histórico
Como a empresa evoluiu, ano a ano. Receita e dívida vêm dos demonstrativos anuais; os dividendos, dos próprios pagamentos, que alcançam mais anos.
As barras são um saldo na data de fechamento; as linhas são o que aconteceu ao longo do ano. Receita acima do patrimônio é o normal, não anomalia — significa que a empresa gira o capital mais de uma vez por ano.
Investidores posicionados
Grandes gestores que reportaram esta ação no 13F mais recente.
Sobre a empresa
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.
- 286
- Fremont, United States
Descrição da empresa fornecida pelo Yahoo Finance. A descrição é publicada pela fonte apenas em inglês.